Business Context and Reporting Period
This Form 8-K is filed by Aquinox Pharmaceuticals, Inc. (not Neurogene Inc.) on August 6, 2015. The report discloses the issuance of a press release regarding financial results for the second quarter ended June 30, 2015, and updates on clinical trial results for its lead candidate, AQX-1125.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the attached press release (Exhibit 99.1), which is incorporated by reference but not detailed within the body of this 8-K.
Material Changes and Clinical Updates
The primary material event reported is the announcement of secondary endpoint results from the Phase 2 LEADERSHIP trial for AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC):
- Primary Endpoint: Previously reported on June 25, 2015, the trial did not reach statistical significance on the primary endpoint, though it showed an encouraging trend in pain reduction.
- Clinical Meaningful Improvement: 49% of patients treated with AQX-1125 achieved a clinically meaningful improvement (2+ points on an 11-point NRS scale) compared to 39% on placebo.
- Secondary Endpoint 1: Statistically significant 1.3-point greater reduction over placebo on maximum daily pain at six weeks (p = 0.030).
- Secondary Endpoint 2: Statistically significant 4.4-point greater reduction over placebo on the O'Leary Sant Symptom Scale at six weeks (p = 0.008).
Outlook and Management Commentary
Management stated that the positive results from the secondary endpoints support the further development of AQX-1125 for BPS/IC. The filing notes that the information is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific Q2 2015 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the regulatory strategy and next steps for AQX-1125 development following the mixed primary endpoint results.
- Review the full statistical analysis of the secondary endpoints to assess the robustness of the p-values reported.
- Check for any updated guidance on cash runway or financing needs given the company's pre-revenue status.